Tryton Completes $20 Million Financing To Accelerate U.S. Pivotal Trial

DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to treat
bifurcation lesions, today announced that the company has closed a $20
million Series D round of financing. Current investors PTV Sciences,
RiverVest Venture Partners and Spray Venture Partners continue to
provide strong support to the company. The financing was lead by private
healthcare investor Arnerich Massena. Russell J. Rottiers from Arnerich
Massena has been appointed to the Tryton Board of Directors.

“We are pleased to welcome Arnerich Massena to our distinguished
investor group,” said J. Greg Davis, president and CEO of Tryton
Medical. “This Series D financing enables us to conduct our U.S. pivotal
trial and drive product adoption internationally.”

Tony Arnerich, CEO of Arnerich Massena, stated, “We are excited to
invest in Tryton and believe the Side Branch stent represents a truly
elegant solution to a difficult clinical problem in interventional
cardiology. With more than 2,000 implants, Tryton has established its
Side Branch stent as the leading solution for these challenging cases.”

The Tryton Side Branch Stent System is designed to offer a dedicated
strategy for treating atherosclerotic lesions in the side branch at the
site of a bifurcation. Tryton’s highly deliverable balloon-expandable
cobalt chromium stent is deployed in the side branch artery using a
standard single-wire stent delivery system. A conventional drugeluting
stent is then placed in the main vessel.

The Tryton Side Branch Stent System demonstrated excellent six-month
clinical and angiographic results in a first-in-man study of the system
and excellent six-month clinical results from almost 200 patients in
four different registries with a rate of target lesion revascularization
of less than four percent.

The stent system has received CE Mark approval in Europe and is
commercially available in 21 countries throughout Europe and the Middle
East. It is not approved in the United States.

About Tryton Medical, Inc.

Tryton Medical, Inc., located in Durham, N.C., is a leading developer of
novel stent systems for the treatment of bifurcation lesions. The Tryton
Side Branch Stent System, approved for sale in Europe, is designed to
offer a dedicated strategy for treating these challenging cases.
Privately held, Tryton is backed by Arnerich Massena & Associates, Spray
Ventures, PTV Sciences, and RiverVest Ventures. For more information
please visit trytonmedical.com.

About Arnerich Massena & Associates

Founded in 1991, Arnerich Massena (www.am-a.com)
is a West Coast-based independent investment advisory firm that offers
services to corporations, institutions, state and local governments,
charitable organizations, trusts and estates, corporate pension and
profit sharing plans, and private clients. Arnerich Massena advises to
more than $14 billion in assets.

About PTV Sciences

PTV Sciences (www.ptvsciences.com),
founded in 2003, is a healthcare venture capital and growth equity firm
focused on building industry leading companies and investing in
extraordinary people. PTV Sciences has a team of investment
professionals and 16 venture partners representing the leading
clinicians, scientists, academic institutions, and entrepreneurs. PTV
Sciences has offices in Austin and Houston, TX.

About RiverVest Venture Partners

RiverVest Venture Partners (www.rivervest.com)
is a venture capital firm investing in emerging medical device,
biopharmaceutical and other healthcare venture opportunities. RiverVest
applies both its capital and its team’s diverse range of expertise to
create and grow successful enterprises that address unmet medical needs
in major markets.

About Spray Venture Partners

Since 1996, Spray (www.spraypartners.com)
has provided capital and management experience to the formation,
financing, and strategic growth of many early-stage medical technology
companies throughout the United States. The firm works closely with
clinical and technical founders to create companies that develop, market
and deploy innovative technologies that meet significant unmet
healthcare needs.